T 1695/07 vom 28.09.2011
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2011:T169507.20110928
- Datum der Entscheidung
- 28. September 2011
- Aktenzeichen
- T 1695/07
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 95902560.2
- IPC-Klasse
- A61M 1/36B01D 61/32
- Verfahrenssprache
- Englisch
- Verteilung
- An die Kammervorsitzenden und -mitglieder verteilt (B)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- -
- Bezeichnung der Anmeldung
- Blood flow measurement method in hemodialysis shunts
- Name des Antragstellers
- TRANSONIC SYSTEMS, INC.
- Name des Einsprechenden
- Fresenius Medical Care Deutschland GmbH
- Kammer
- 3.3.07
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 111(1)European Patent Convention Art 123(2)European Patent Convention Art 52(4) 1973European Patent Convention Art 53(c)European Patent Convention Art 56European Patent Convention Art 84 1973
- Schlagwörter
- Exception to patentability (yes) - Main Request and Auxiliary Request 1
Disclaimer admissible (no) - Auxiliary Request 2
Exception to patentability (no) - apparatus - Auxiliary Requests 3 and 4
Amendments - Clarity (no) - Auxiliary Requests 3 and 4
Amendments - allowable (yes) - Auxiliary Request 5
Inventive step (yes) - non obvious solution - Auxiliary Request 5
Remittal (yes) - description yet to be adapted - Orientierungssatz
- I. A blood manipulation process involving the continuous removal of blood from a patient, its subsequent flowing through a circulating line of an extracorporeal circuit and its re-delivery to the patient is a method of treatment of the human body by surgery excepted from patentability under Article 53(c) EPC. It does not belong to the kind of methods which should not be covered by the exception clause according to the "narrower understanding" suggested by the Enlarged Board of Appeal in decision G 1/07, because the process is not performed in a "non-medical, commercial environment" and cannot be considered as a "minor intervention" being performed on "uncritical parts of the body" (Reasons, 8 to 10).
II. Such an in vivo process requires "professional medical expertise" and belongs to the kind of interventions representing the "core of the medical profession's activities", even when performed by paramedical support staff (Reasons, 11).
III. Even when the process is carried out with the required medical professional care and expertise, it involves "substantial health risks" for the patient. A health risk is considered to qualify as "substantial" whenever it goes beyond the side effects associated with treatments such as tattooing, piercing, hair removal by optical radiation, micro abrasion of the skin as mentioned in G 1/07. A factual analysis of absolute or relative risks and their likelihood of occurrence based on objective evidence is hardly feasible and should therefore not be required (Reasons, 12).
ORDER
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the department of first instance with the order to maintain the patent on the basis of the claims of Auxiliary Request 5 filed with letter dated 5 September 2011 and a description to be adapted thereto.